- Home
- URGN vs CHCT Comparison
URGN vs CHCT Comparison
Compare URGN & CHCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CHCT
- Stock Information
- Founded
- URGN 2004
- CHCT 2014
- Country
- URGN United States
- CHCT United States
- Employees
- URGN N/A
- CHCT N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CHCT Real Estate Investment Trusts
- Sector
- URGN Health Care
- CHCT Real Estate
- Exchange
- URGN Nasdaq
- CHCT Nasdaq
- Market Cap
- URGN 463.2M
- CHCT 422.2M
- IPO Year
- URGN 2017
- CHCT 2015
- Fundamental
- Price
- URGN $4.24
- CHCT $16.34
- Analyst Decision
- URGN Strong Buy
- CHCT Buy
- Analyst Count
- URGN 8
- CHCT 4
- Target Price
- URGN $27.92
- CHCT $21.00
- AVG Volume (30 Days)
- URGN 2.4M
- CHCT 196.0K
- Earning Date
- URGN 05-12-2025
- CHCT 07-29-2025
- Dividend Yield
- URGN N/A
- CHCT 11.41%
- EPS Growth
- URGN N/A
- CHCT N/A
- EPS
- URGN N/A
- CHCT N/A
- Revenue
- URGN $91,871,000.00
- CHCT $116,531,000.00
- Revenue This Year
- URGN $35.06
- CHCT $7.14
- Revenue Next Year
- URGN $112.94
- CHCT $7.04
- P/E Ratio
- URGN N/A
- CHCT N/A
- Revenue Growth
- URGN 8.98
- CHCT 1.33
- 52 Week Low
- URGN $3.42
- CHCT $14.76
- 52 Week High
- URGN $20.70
- CHCT $27.62
- Technical
- Relative Strength Index (RSI)
- URGN 27.72
- CHCT 48.18
- Support Level
- URGN $3.71
- CHCT $15.62
- Resistance Level
- URGN $4.25
- CHCT $16.85
- Average True Range (ATR)
- URGN 0.91
- CHCT 0.39
- MACD
- URGN -0.45
- CHCT 0.02
- Stochastic Oscillator
- URGN 9.87
- CHCT 54.96
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.